Download PDF
Thromb Haemost 1988; 60(01): 083-087
DOI: 10.1055/s-0038-1647640
Original Article
Schattauer GmbH Stuttgart

Platelet Function and the Bleeding Time in Progressive Renal Failure

M P Gordge
The Dept. of Renal Medicine, Institute of Urology, St. Philips Hospital, London, UK
,
R W Faint
The Dept. of Renal Medicine, Institute of Urology, St. Philips Hospital, London, UK
,
P B Rylance
The Dept. of Renal Medicine, Institute of Urology, St. Philips Hospital, London, UK
,
G H Neild
The Dept. of Renal Medicine, Institute of Urology, St. Philips Hospital, London, UK
› Author Affiliations
Further Information

Publication History

Received 07 October 1987

Accepted after revision 18 April 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Bleeding time and platelet function tests were performed on 31 patients with progressive chronic renal failure (CRF) due to non-immunological (urological) causes, and compared with 22 healthy controls. Patients were classified as mild (plasma creatinine <300 μmol/l), moderate (300-600 μmol/l) or severe renal failure (>600 μmol/l). Bleeding time was rarely prolonged in mild and moderate CRF and mean bleeding time significantly elevated only in severe CRF (p <0.005). Haematocrit was the only index which correlated with bleeding time (r = -0.40). Platelet counts, collagen stimulated thromboxane generation, and platelet aggregation responses to ADP, collagen and ristocetin were all either normal or increased in all three CRF groups, but thromboxane production in clotting blood was reduced. Plasma fibrinogen, C reactive protein and von Willebrand factor (vWF) were elevated in proportion to CRF. We found no evidence that defects in platelet aggregation or platelet interaction with vWF prolong the bleeding time in patients with progressive CRF.

Key words

Platelets - Bleeding time - Renal failure
 

  • References

  • 1 Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uraemia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-117
    CrossrefPubMedGoogle Scholar
  • 2 Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uraemia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559
    CrossrefPubMedGoogle Scholar
  • 3 Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day JS, Smith WL, Pinea E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uraemia. Evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71: 762-768
    CrossrefPubMedGoogle Scholar
  • 4 Turney JH, Woods HF, Fewell MR, Weston MJ. Factor VIII complex in uraemia and the effects of haemodialysis. Br Med J 1981; 282: 1653-1656
    CrossrefPubMedGoogle Scholar
  • 5 Veiner A, Aviram M, Better OS, Brook JG. Enhanced in vitro platelet aggregation in haemodialysis patients. Nephron 1986; 43: 139-143
    CrossrefPubMedGoogle Scholar
  • 6 Bloom A, Greaves M, Preston FE, Brown CB. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 1986; 62: 143-149
    CrossrefPubMedGoogle Scholar
  • 7 Rylance PB, Gordge MP, Weston MJ. Platelet function is enhanced, not reduced in uraemia. Proc Eur Dial Transplant Assoc 1985; 22: 946-952
    PubMedGoogle Scholar
  • 8 Remuzzi G, Marchesi D, Cavenaghi AE, Livio M, Donati MB, De Gaetano G, Mecca G. Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2). Clin Nephrol 1979; 12: 127-131
    PubMedGoogle Scholar
  • 9 Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uraemic patients. Blood 1986; 68: 337-342
    PubMedGoogle Scholar
  • 10 Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM, Boneu B. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusion. Br J Haematol 1985; 59: 139-148
    CrossrefPubMedGoogle Scholar
  • 11 Rylance PB, Gordge MP, Weston MJ. Correction of citrate concentration is necessary in platelet aggregometry studies in uraemia. Clin Nephrol 1985; 23: 155-156
    PubMedGoogle Scholar
  • 12 Kelton JG, Powers P, Julian J, Boland V, Carter C, Gent M, Hirsh J. Sex-related differences in platelet aggregation: influence of the haematocrit. Blood 1980; 56: 38-41
    PubMedGoogle Scholar
  • 13 Carter AJ, Hanley SR. The effect of platelet number and haematocrit on whole blood thromboxane synthesis. Thromb Haemostas 1985; 53: 225-227
    PubMedGoogle Scholar
  • 14 Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basle) 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 15 Cameron JS. Platelets in glomerular disease. Ann Rev Med 1984; 35: 175-180
    CrossrefPubMedGoogle Scholar
  • 16 Colwell JA, Halushka PV. Platelet function in diabetes mellitus. Br J Haematol 1980; 44: 521-526
    CrossrefPubMedGoogle Scholar
  • 17 Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; 2: 219-222
    PubMedGoogle Scholar
  • 18 Greer IA, Walker JJ, McLaren M, Calder AA, Forbes CD. A comparative study of the effects of adrenoreceptor antagonists on platelet aggregation and thromboxane generation. Thromb Haemostas 1985; 54: 480-484
    PubMedGoogle Scholar
  • 19 Onoda JM, Sloane BF, Honn KV. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthetase inhibitors. Thromb Res 1984; 34: 367-378
    CrossrefPubMedGoogle Scholar
  • 20 Doyle VM, Ruegg UT. Lack of evidence for voltage operated calcium channels on platelets. Biochem Biophys Res Commun 1985; 12: 161-167
    PubMedGoogle Scholar
  • 21 Takahara K, Kuroiwa A, Matshushima T, Nakashima Y, Takasugi M. Effects of nifedipine on platelet function. Am Heart J 1985; 109: 4-8
    CrossrefPubMedGoogle Scholar
  • 22 Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534
    CrossrefPubMedGoogle Scholar
  • 23 Milani L, Merkel C, Canel F, Gasparotto ML, Gatta A. Relationship between plasma levels of factor VIII related antigen and reticulo-endothelial function in chronic uraemia. Clin Nephrol 1983; 20: 235-238
    PubMedGoogle Scholar
  • 24 Brunner FP, Brynger H, Chantier C, Donckerwolke RA, Hathway RA, Jacobs C, Selwood NH, Wing AJ. Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 1978; 16: 28-29
    PubMedGoogle Scholar
  • 25 Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 1985; 82: 193-197
    CrossrefPubMedGoogle Scholar
  • 26 Janson PA, Jubilirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uraemia with cryoprecipitate. N Engl J Med 1980; 303: 1318-1322
    CrossrefPubMedGoogle Scholar
  • 27 Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G. Deamino-8-d-arginine vasopressin shortens the bleeding time in uraemia. N Engl J Med 1983; 308: 8-12
    CrossrefPubMedGoogle Scholar
  • 28 Livio M, Mannucci PM, Vigano G, Mingardi G, Lombardi R, Mecca G, Remuzzi G. Conjugated oestrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315: 731-735
    CrossrefPubMedGoogle Scholar
  • 29 Andrassy K, Ritz E. Uraemia as a cause of bleeding. Am J Nephrol 1985; 5: 313-319
    CrossrefPubMedGoogle Scholar